The addition of rituximab to CHOP was markedly more beneficial in GCB-DLBCL patients with high WEE1 expression than in patients with low WEE1 expression (Hazard Ratio (HR) of 2.8, CI 1.5–5.1, p = 0.001 vs HR 2.0. Here, WEE1 is linked to diffuse large B-cell lymphoma.